Compare e l f Beauty Inc (ELF) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
e l f Beauty Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? e l f Beauty Inc trades at $108.13 (market cap $6.38B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: e l f Beauty Inc is far larger — about 6.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and e l f Beauty Inc is more actively traded (856,198 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold e l f Beauty Inc for 26 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ELF | MRVI | |
|---|---|---|
Market Cap | $6.38B | $972.90M |
Volume | 856,198 | 4,325,710 |
Sector | Consumer Staples | Health |
52-Week High | $136.92 | $9.00 |
52-Week Low | $49.57 | $2.83 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $6.97B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum showing bullish moving averages but overbought RSI readings. The company demonstrates robust revenue growth with Q2 2026 earnings beating expectations by 145%, though valuation metrics remain elevated with a P/E of 110.37. Recent expansion includes rhode brand launches in 19 European markets via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album.
Outlook remains positive with analyst consensus leaning bullish (48% buy ratings) despite premium valuation. Key opportunities include international expansion and market share gains, while risks center on margin compression and competitive pressures in the beauty sector. The stock trades above consensus price target of $95.91, suggesting near-term consolidation potential.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
